PTO/SB/26 (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING	Docket Number (Optional)
REJECTION OVER A "PRIOR" PATENT	16534-539001US
In re Application of: Stuart B. Levy et al.	
Application No.: 10/692,764	
Filed: October 24, 2003	
For: Methods of Using Substituted Tetracycline Compounds to Modulate RNA	
The owner*, Paratek Pharmaceuticals, Inc. , of	
2. X The undersigned is an attorney or agent of record. Reg. No. 45,409	
DATMUM	August 23, 2011
Signature	Date
Heidi A. Erlacher, J.D., Ph.D.	
Typed or printed name	
	(617) 348-4909
	Telephone Number
X Terminal disclaimer fee under 37 CFR 1.20(d) is included.	
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.	
*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this certification. See MPEP § 324.	